NCT04127006 (Pro-EYS) is a clinical trial in Retinitis Pigmentosa, sponsored by Jaeb Center for Health Research.

Who is sponsoring NCT04127006?

NCT04127006 is sponsored by Jaeb Center for Health Research.

What condition does NCT04127006 study?

NCT04127006 studies Retinitis Pigmentosa, Eye Diseases.

Is NCT04127006 still recruiting?

NCT04127006 is currently active, enrolled. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT04127006: Pro-EYS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rate of Progression in EYS Related Retinal Degeneration

Active, enrolled Last updated 4 March 2026

What this trial tests

trial in Retinitis Pigmentosa in 103 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 February 2020

Primary endpoint
1 April 2026

1 April 2026

Quick facts

Lead sponsor	Jaeb Center for Health Research
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	103
Start date	25 February 2020
Primary completion	1 April 2026
Estimated completion	1 April 2026
Sites	19 locations across France, Finland, Netherlands, Germany, Israel, Canada, United States

Conditions studied

Retinitis Pigmentosa — all drugs for Retinitis Pigmentosa →
Eye Diseases — all drugs for Eye Diseases →

Sponsor

Jaeb Center for Health Research — full company profile →

Who can join

18 and older, any sex, with Retinitis Pigmentosa or Eye Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall goal of this project funded by the Foundation Fighting Blindness is to characterize the natural history of disease progression in patients with EYS mutations in order to accelerate the development of outcome measures for clinical trials.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Implementation of a registry and open access genetic testing program for inherited retinal diseases within a non-profit foundation.
Mansfield BC, Yerxa BR, Branham KH. · · 2020 · cited 27× · PMID 32783387 · DOI 10.1002/ajmg.c.31825
Natural history of retinitis pigmentosa based on genotype, vitamin A/E supplementation, and an electroretinogram biomarker.
Comander J, Weigel DiFranco C, Sanderson K, Place E, et al · · 2023 · cited 25× · PMID 37261916 · DOI 10.1172/jci.insight.167546
The double-edged sword of inflammation in inherited retinal degenerations: Clinical and preclinical evidence for mechanistically and prognostically impactful but treatable complications.
Sarici K, Vyas A, Iannaccone A. · · 2023 · cited 11× · PMID 37123408 · DOI 10.3389/fcell.2023.1177711
Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium.
Durham TA, Duncan JL, Ayala AR, Birch DG, et al · · 2021 · cited 9× · PMID 34004001 · DOI 10.1167/tvst.10.4.23
The Importance of Natural History Studies in Inherited Retinal Diseases.
Ayala A, Cheetham J, Durham T, Maguire M. · · 2023 · cited 8× · PMID 36690461 · DOI 10.1101/cshperspect.a041297
Inherited Retinal Degenerations and Non-Neovascular Age-Related Macular Degeneration: Progress and Unmet Needs.
Duncan JL, Bowman A, Laster A, Gelfman C, et al · · 2024 · cited 5× · PMID 39688851 · DOI 10.1167/tvst.13.12.28
Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium.
Thompson DA, Jayasundera KT, Alekseev O, Ali RR, et al · · 2025 · cited 2× · PMID 40862658 · DOI 10.1167/tvst.14.8.37

Verify or expand the search:

Other recruiting trials for Retinitis Pigmentosa

Currently open trials in the same condition.

NCT06891885 — A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years · Phase 1, PHASE2 · recruiting
NCT07408232 — A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) · Phase 1, PHASE2 · recruiting
NCT07228793 — Natural History Study of Patients With EYS-Associated RP · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06936787 — An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa · Phase 1 · recruiting

Other Jaeb Center for Health Research trials

Trials by the same sponsor.

NCT07496515 — Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia · Phase 2 · not yet recruiting
NCT07095894 — A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control · Phase 3 · not yet recruiting
NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
NCT06880835 — Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automate · NA · recruiting
NCT06957028 — CGM for the Early Detection and Management of Hyperglycemia in Pregnancy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04127006 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jaeb Center for Health Research
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04127006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing